By Ayo Ajayi
In a significant breakthrough in the fight against malaria, researchers from Covenant University in Nigeria and the German Cancer Research Center have discovered a new class of organic compounds with potent antimalarial properties.
The discovery, published in the Arabian Journal of Chemistry, introduces a novel approach to malaria treatment by targeting a little-known enzyme critical to the malaria parasite’s survival.
Malaria continues to pose a serious global health challenge, with 247 million cases reported worldwide by the World Health Organization (WHO). Africa bears the highest burden, and children under five remain the most vulnerable, making up 76% of all malaria-related deaths.
The growing resistance of Plasmodium falciparum, the deadliest malaria parasite, to existing drugs has created an urgent need for new and effective therapies.
The research team behind this breakthrough includes Olayinka O. Ajani, Gbolahan O. Oduselu, and Damilola V. Aderohunmu from the Department of Chemistry; Glory P. Adebayo and Grace I. Olasehinde from the Department of Biological Sciences; and Ezekiel Adebiyi from the Department of Computer Science—all of Covenant University, Nigeria. They collaborated with Karel D. Klika of the German Cancer Research Center (DKFZ).
Together, they targeted an underexplored parasite enzyme known as Plasmodium falciparum 6-pyruvoyltetrahydropterin synthase (PfPTPS), using structure-based drug design to synthesize new compounds that disrupt its activity.
Among the compounds developed, one stood out—4-aminobenzenecarbohydroxamic acid (3b). It showed remarkable potency in lab tests with an IC₅₀ of less than 0.2 μM, inhibited the target enzyme effectively, and demonstrated no toxicity to mammalian cells.
Further testing in rodents confirmed the compound's safety and therapeutic potential. Computer simulations revealed that the compound binds tightly to the enzyme by interacting with a zinc ion at its active site, confirming its mechanism of action.
What sets this discovery apart is that these compounds work differently from current antimalarial drugs, making them especially valuable in the face of growing drug resistance.
“This research lays the foundation for a new generation of antimalarial treatments,” the authors noted, emphasizing the need for further development and clinical trials.
Published in a Q1 journal with an impact factor of 5.3, the study is available online at https://doi.org/10.1016/j.arabjc.2023.105573. The researchers hope their findings will attract further investment and collaboration to help turn these promising compounds into life-saving medicines.
